Pharmacogenetic evidence that cd36 is a key determinant of the metabolic effects of pioglitazone

0142374 - FGU-C 20020105 RIV US eng J - Journal Article
Qi, N. - Kazdová, L. - Zídek, Václav - Landa, Vladimír - Křen, Vladimír - Pershadsingh, H. A. - St.Lezin, E. - Abumrad, N. A. - Pravenec, Michal - Kurtz, W. T.
Pharmacogenetic evidence that cd36 is a key determinant of the metabolic effects of pioglitazone.
Journal of Biological Chemistry. Roč. 277, č. 50 (2002), s. 48501-48507. ISSN 0021-9258. E-ISSN 1083-351X
R&D Projects: GA ČR GA301/00/1636; GA ČR GV204/98/K015; GA MŠMT LN00A079
Grant - others:HHMI(US) 55000331
Institutional research plan: CEZ:AV0Z5011922
Keywords : thiazolidinedione * Cd36 * transgenic SHR
Subject RIV: EB - Genetics ; Molecular Biology
Impact factor: 6.696, year: 2002

295 To specifically investigate the role of the Cd36 fatty acid transporter gene in the insulin sensitizing actions of thiazolidinediones, we studied the metabolic effects of pioglitazone in spontaneously hypertensive rats (SHR) that harbor a deletion mutation in Cd36 in comparison to congenic and transgenic strains of SHR that express wild type Cd36. Our findings provide direct pharmacogenetic evidence that in the SHR model, Cd36 is a key determinant of the insulin sensitizing actions of a thiazolidinedione ligand of PPAR?.
Permanent Link: http://hdl.handle.net/11104/0040080